Mustang Bio announces scientific presentations on MB-101 (IL13R? 2? Targeted CAR T cells) at upcoming virtual conferences
The details of the virtual presentations are as follows:
First Annual CNS Clinical Trials Conference, co-sponsored by the
Title: CAR T cells in primary brain tumors
Session: Session 3: Immunotherapy – Hype and Hope
Date and time:
Title: Advancing CAR T Cell Therapy for Glioblastoma
Session: Plenary session 2: New therapeutics
Date and time:
Mustang is collaborating with City of Hope on several chimeric antigen receptor T cell clinical trials, including the MB? 101 (IL13R? 2? CAR T cell targeted) clinical trials for brain cancer. Additional information on clinical brain cancer trials can be found at clinicaltrials.gov using the identifiers NCT04661384, NCT02208362 and NCT04003649.
About MB? 101 (IL13R? 2? Targeted CAR T cells)
IL13R? 2 is an attractive target for CAR T therapy because it has limited expression in normal tissues but is overexpressed on the surface of the majority of malignant glioma cells, including glioblastoma multiforme, ependymoma, and medulloblastoma. CAR T cells are engineered to express a membrane-bound IL-13 receptor ligand (IL-13) incorporating a unique point mutation that provides high affinity for IL13R-2 and reduces binding to IL13R-1 to reduce IL13R-1 binding. targeting healthy tissue. Mustang develops MB? 101 as an optimized CAR T product incorporating improvements in CAR design and T cell engineering to improve antitumor potency and T cell persistence. MB? 101 includes an optimized CAR for the second hinge generation containing mutations in the IgG4 linker to reduce off-target Fc interactions, the costimulatory signaling domain 4-1BB (CD137) for enhanced CAR T cell persistence and the extracellular domain of CD19 as a selection / safety marker. To further improve persistence, central memory T cells are enriched and genetically engineered using a manufacturing process that limits ex vivo expansion to reduce T cell depletion and maintain a memory T cell phenotype. .
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks related to the results of research and development activities; risks associated with the timing of the initiation and completion of clinical trials; uncertainties relating to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our
T: (781) 652-4500
Phone. : (617) 430-7576
T: (908) 591-2839